BMJ Open Socioeconomic inequalities in cervical precancer screening among women in Ethiopia, Malawi, Rwanda, Tanzania, Zambia and Zimbabwe: analysis of **Population-Based HIV Impact Assessment surveys**

David Chipanta (1), 1,2 Sharon Kapambwe (10), 3 Alinane Linda Nyondo-Mipando (10), 4 Margaret Pascoe (10), 5 Silas Amo-Agyei (10), 6 Julia Bohlius , ⁷ Janne Estill , ² Olivia Keiser

To cite: Chipanta D. Kapambwe S, Nyondo-Mipando AL, et al. Socioeconomic inequalities in cervical precancer screening among women in Ethiopia, Malawi, Rwanda, Tanzania, Zambia and Zimbabwe: analysis of Population-Based HIV Impact Assessment surveys. BMJ Open 2023;13:e067948. doi:10.1136/ bmjopen-2022-067948

Prepublication history and additional supplemental material for this paper are available online. To view these files. please visit the journal online (http://dx.doi.org/10.1136/ bmjopen-2022-067948).

Received 02 September 2022 Accepted 30 May 2023



@ Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr David Chipanta; chipanta@hotmail.com

ABSTRACT

Objectives We examined age, residence, education and wealth inequalities and their combinations on cervical precancer screening probabilities for women. We hypothesised that inequalities in screening favoured women who were older, lived in urban areas, were more educated and wealthier.

Design Cross-sectional study using Population-Based HIV Impact Assessment data.

Setting Ethiopia, Malawi, Rwanda, Tanzania, Zambia and Zimbabwe. Differences in screening rates were analysed using multivariable logistic regressions, controlling for age, residence, education and wealth. Inequalities in screening probability were estimated using marginal effects models. Participants Women aged 25-49 years, reporting screening.

Outcome measures Self-reported screening rates, and their inequalities in percentage points, with differences of 20%+ defined as high inequality, 5%-20% as medium, 0%-5% as low.

Results The sample size of participants ranged from 5882 in Ethiopia to 9186 in Tanzania. The screening rates were low in the surveyed countries, ranging from 3.5% (95% CI 3.1% to 4.0%) in Rwanda to 17.1% (95% CI 15.8% to 18.5%) and 17.4% (95% CI 16.1% to 18.8%) in Zambia and Zimbabwe. Inequalities in screening rates were low based on covariates. Combining the inequalities led to significant inequalities in screening probabilities between women living in rural areas aged 25-34 years, with a primary education level, from the lowest wealth quintile, and women living in urban areas aged 35-49 years, with the highest education level, from the highest wealth quintile, ranging from 4.4% in Rwanda to 44.6% in

Conclusions Cervical precancer screening rates were inequitable and low. No country surveyed achieved onethird of the WHO's target of screening 70% of eligible women by 2030. Combining inequalities led to high inequalities, preventing women who were younger, lived in rural areas, were uneducated, and from the lowest wealth

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ Collinearity was present, especially between the wealth and residence variables which tend to correlate with each other, consistent with how the wealth variable is constructed.
- ⇒ Recall bias was present as cervical precancer screening is self-reported.
- ⇒ We did not control for the type of cervical precancer screening because we did not have information on the types of screening women received.

quintile from screening. Governments should include and monitor equity in their cervical precancer screening programmes.

INTRODUCTION

Although all countries are affected by cervical cancer, its incidence and mortality are more than twice and three times as high in low-income and middle-income countries as in high-income countries. In 2020, it was the leading cause of cancer deaths in 36 countries. Most of these countries were in sub-Saharan Africa, Melanesia, South America and South-Eastern Asia.² Cervical cancer occurs in the lower part of the uterus that connects to the vagina. It is caused in over 70% of cases by the human papillomavirus (HPV), the most common sexually transmitted infection (STI). Most HPV strains are harmless in people with a healthy immune system. HIV-positive women, whose immunity may be compromised, 1 2 are six times more likely to develop cervical cancer than HIV-negative women. In 2014, invasive cervical cancer was 11 times higher



among women living with HIV in South Africa than in Europe 5 years after antiretroviral therapy (ART) initiation.³ Cervical cancer harms girls, women and their families with significant health and development consequences, yet it is preventable and curable if detected and treated early. 12 HPV vaccination and regular precancer screening stop cervical precancer. Cervical precancer screening identifies precancerous cells to treat before they become cancer. 1 Comprehensive HPV vaccination and cervical precancer screening could prevent an estimated 5.2 million cases and 3.7 million deaths over 10 years and would cost around US\$3.2 billion in 50 low-income and lower-middle-income countries. 4 In 2020, the WHO proposed the 90-70-90 target, which, if achieved by 2030, would put the world on course to eliminate cervical cancer. The 90–70–90 target seeks to ensure that 90% of girls are vaccinated against HPV by age 15 years, 70% of eligible women are screened by age 35 years and again by 45, and 90% of women identified with cervical cancer receive treatment.

Cervical cancer is a disease of inequality. Its burden reflects inequalities in society, including those related to socioeconomic status. Inequality in health and healthcare is defined as the unequal distribution of health goods, services and outcomes across income or other measures of wealth. In contrast, equity is the lack of avoidable and remedial differences in the distribution of health goods and services or outcomes due to people's socioeconomic status in society.^{5–7} Cervical precancer screening is a critical component of the 90-70-90 target. Socioeconomic inequalities are preventing women from accessing cervical precancer screening. Studies show that residence, geography, education, wealth, age, health insurance status and the capacity of health systems influence access to cervical precancer screening. Other factors include, a history of multiple sexual partners, HIVpositive status and women's social interactions. 9-18 These studies showed that women who were older, resided in urban areas, and were more educated and wealthier were screened more often than women who were younger, resided in rural areas, were uneducated and poor, with a few exceptions. 9 19-22 However, these studies did not estimate the magnitude of inequalities and their combined impact on cervical precancer screening. Such studies are needed to scale up cervical precancer screening and support the prioritisation of inequalities to eliminate cervical cancer, especially in east and southern African countries, where HIV has worsened the cervical cancer burden.²³ This study aimed to examine age, residence, education, and wealth related inequalities and their combined impacts on cervical precancer screening in Ethiopia, Malawi, Rwanda, Tanzania, Zambia and Zimbabwe. We hypothesised that significant inequalities in cervical precancer screening rates would favour older women, women who resided in urban areas, and more educated and wealthier women.

METHODS

Data and sample

This is cross-sectional study of a secondary data analysis of available Population-Based HIV Impact Assessment (PHIA) data for countries that included cervical precancer screening variables. The countries and the years in which the PHIA surveys were conducted include Ethiopia (2017–2018), 24 Malawi (2015–2016), 25 Rwanda (2018–2019), ²⁶ Tanzania (2016–2017), ²⁷ Zambia (2016) ²⁸ and Zimbabwe (2015–2016). ²⁹ The PHIA surveys collected a range of health and sociodemographic data to evaluate the impact of HIV programmes in countries supported by US President's Emergency Plan for AIDS Relief. We used the Household, and Adult data sets. In participating households, a household questionnaire was administered to the head-of-household, who provided information on the household relating to wealth, and other sociodemographic characteristics. Then, an individual questionnaire was administered to eligible and consenting adults aged 15 years or older in the household. The individual interviews assessed a range of HIV-related variables, including cervical precancer screening and HIV testing.

We restricted our analysis to women aged 25–49 years who responded to the cervical precancer questions. This is the group WHO recommends for cervical precancer screening—ages 30–49 years for the general population and 25–49 years for women living with HIV—including all gender diverse people at risk of cervical cancer.¹

Patient and public involvement

No patient involved.

Variables and outcome descriptions

We assessed inequalities related to age, residence, education and wealth in cervical precancer screening according to women's self-reports. These dimensions of inequalities are familiar sources of disadvantage or discrimination.³⁰ Our primary outcome was self-reported ever testing for cervical precancer. The main predictors were age, residence, education and wealth. Other covariates were having ever been married, ever been tested for HIV, (also binary coded) and regions. Regions, provinces or zones were coded as dummy variables and included to capture the geographical variation in cervical precancer screening. Ethiopia's data set had an urban variable, which we coded as rural if the population size was smaller than 50000 people and urban otherwise. Online supplemental table 1 describes the variables. We used percentages to measure the magnitude of inequality between subgroups. We denoted a difference of 20% or more between two subgroups as high inequality, less than 20% but greater than 5% as medium inequality and below 5% as low inequality, as used by the WHO.³⁰

Analysis

We assessed inequalities in self-reported cervical precancer screening in three steps. For each country, we first presented sample characteristics descriptively. Second, we determined the associations between screening for cervical precancer and each dimension of inequality, and analysed the differences using multivariable logistics regression, controlling for covariates. We corrected the p values of odds ratios (OR) for multiple hypothesis testing with sharpened q's. In step 3, we used marginal effects models to estimate the probabilities of reporting cervical precancer screening for each inequality alone and combined with other inequalities, holding the other inequalities constant at their mean values. We applied survey weights to account for complex survey design. Using jack-knife replicate weights, 95% CIs were estimated.³¹ We excluded the observation from the analysis if the gender value was missing. We did not impute the missing data since all variables had less than 2% of missing values. We used Stata V.14 for the analyses.³² This study conforms to the Standards for Quality Improvement Reporting Excellence (SQUIRE) reporting guidelines. 33

RESULTS

The sample size of females aged 25–49 years ranged from 5882 in Ethiopia to 9186 in Tanzania. The median age and Interquartile ranges (IQRs) were 32 years ^{28–39} in Ethiopia, 33 years^{29–40} in Zambia and 34 years^{29–40} in Malawi, Rwanda and Tanzania. The rate of self-reported cervical precancer screening was lowest in Rwanda (3.5% (95% CI 3.1% to 4.0%)) and highest in Zambia (17.1% (95%) CI 15.8% to 18.5%)) and Zimbabwe (17.4% (95% CI 16.1% to 18.8%)). The HIV prevalence among females aged 25-49 years old ranged from 4.7% (95% CI 4.1% to 5.4%) in Rwanda to 22.6% (95% CI 21.6% to 23.7%) in Zimbabwe, and the rate of cervical precancer screening among HIV-positive females ranged from 0.4% (95% CI 0.3% to 0.5%) in Rwanda to 5.4% (95% CI 4.7% to 6.1%) in Zambia. Females aged 25-34 years comprised half or more of the sample in surveyed countries. Eighty-six per cent or more of the respondents reported ever having been married, and 86% or more reported ever having been tested for HIV. More than half of the respondents resided in rural areas, excluding Ethiopia, where all respondents resided in urban areas, 54% of them in areas with <50 000 residents. Less than 20% of the respondents were uneducated, and nearly 30% had attained a primary school education. Only in Ethiopia, Malawi and Zambia was the proportion of respondents in the top two wealth quintiles greater than that in the bottom two quintiles (table 1).

Figure 1 shows the proportion of respondents reporting screening for cervical precancer by age group (25-34 vs 35-49-year-olds), residence (rural vs urban), education level and wealth quintile by country and table 2 presents adjusted ORs. In all countries except Zambia, more 35-49-year-olds than 25-34-year-olds reported screening for cervical precancer (figure 1). Age-related differences in reported screening varied and ranged in percentage points from 0.2% (1.7% among 25-34-year-olds vs 1.9%

among 35–49-year-olds) in Rwanda to 2.8% (7.3% among 25–34-year-olds vs 10.1% among 35–49-year-olds) in Zimbabwe. After adjusting for covariates, 35–49-year-olds in all countries surveyed reported being more likely to be screened for cervical precancer than 25-34-year-olds (table 2).

More urban residents than rural residents reported screening for cervical precancer in Ethiopia, Tanzania, Zambia and Zimbabwe before adjusting for covariates (figure 1). In these countries, the rural-urban inequalities in cervical precancer screening were low, except in Zambia (5.1%, moderate). After adjustment, more urban residents than rural residents in Ethiopia, Malawi, Rwanda and Tanzania reported screening for cervical precancer (table 2).

Respondents in Malawi, Rwanda, Zambia and Zimbabwe had education-related inequalities (figure 1). Education-related inequalities were also low in these countries except Zambia, where it was moderate between the uneducated and those with secondary schooling (5.9%). Respondents in Malawi, Tanzania, Zambia and Zimbabwe had significant wealth-related inequalities in cervical precancer screening (figure 1 and table 2). In Malawi and Tanzania, the inequalities between respondents in the lowest and highest wealth quintiles were low—4.9% and 1.9%, respectively. They were moderate in Zambia (5.7%) and Zimbabwe (5.3%) (figure 1). The goodness-of-fit test showed that our models fit the data well (table 2).

Figure 2 shows the probabilities of self-reported cervical precancer screening for selected combinations of age group (25–34, 35–49-year-olds), residence (rural, urban), education level and wealth quintile in percentage points by country. There were significant differences in cervical screening probabilities between the rural residents in the lowest wealth quintile with no education aged 25-34 years (25-34#Rural#Noed#1 in figure 2) and their urban residents peers in the highest wealth quintile, highest educated (25-34#Urban#High#5) in figure 2, ranging from 3.3% in Rwanda to 29.0% in Zambia. When similar comparisons were made for 35-49-year-olds, the differences ranged from 3.6% in Rwanda to 38.8% in Zimbabwe. A comparison of rural residents aged 25-34 years old, with primary education in the second wealth quintile (25-34#Rural#Prim#2) and urban residents aged 35-49 years old, with the highest education in the highest wealth quintile (35–49#Urban#High#5), showed substantially increased differences, ranging from 4.4% in Rwanda to 44.6% in Zimbabwe. Inequalities between urban residents aged 25-34 years old, with the highest education, in the highest wealth quintile (25-34#Urban#High#5) and urban residents aged 35-49 years old, with the highest education, in the highest wealth quintile (35-49#Urban#High#5) were moderate in magnitude, except in Rwanda where they were low (figure 2).

BMJ Open: first published as 10.1136/bmjopen-2022-067948 on 20 June 2023. Downloaded from http://bmjopen.bmj.com/ on June 29, 2023 at University of Basel. Protected by copyright.

| Table 1 Survey weighted sample characteristics by country | ample characteristics by | / country (PHIA 2015-20 | (PHIA 2015-2019), (percentage (95% CI) sample size) | (I) sample size) | | |
|---|--|---|---|---|---|---------------------------|
| | Ethiopia | Malawi | Rwanda | Tanzania | Zambia | Zimbabwe |
| Cervical precancer screened | 6.1 (5.3 to 6.9), 343 | 11.8 (10.6 to 13.1), 926 | 3.5 (3.1 to 4.0), 353 | 7.0 (6.1 to 8.1), 586 | 17.1 (15.8 to 18.5), 1066 | 17.4 (16.1 to 18.8), 1129 |
| HIV positive | 6.1 (5.3 to 7.0), 362 | 18.8 (17.3 to 20.3), 1152 | 4.7 (4.1 to 5.4), 416 | 9.2 (8.4 to 10.0), 897 | 21.2 (19.8 to 22.6), 1263 | 22.6 (21.6 to 23.7), 1602 |
| Cervical precancer screened | 0.9 (0.7 to 1.45), 52 | 3.4 (2.8 to 4.1), 249 | 0.4 (0.3 to 0.5), 43§ | 1.5 (1.1 to 2.0), 132 | 5.4 (4.7 to 6.1), 318 | 4.5 (4.0 to 5.0), 305 |
| Age (years): median (IQR) years 32 (28 | 32 (28 to 39) | 34 years (29 to 40) | 34 years (29 to 40) | 34 years (29 to 40) | 33 years (29 to 40) | 34 years (29 to 40) |
| 25–34 | 55.9 (55.7 to 56.2), 3517 | 53.0 (52.9 to 53.1), 3342 | 52.1 (52.1 to 52.2), 4508 | 52.2 (52.2 to 52.3), 4812 | 55.3 (55.2 to 55.4), 3386 | 54.5 (54.4 to 54.6), 3403 |
| 35–49 | 44.1 (43.8 to 44.3), 2365 | 44.1 (43.8 to 44.3), 2365 47.0 (46.9 to 47.1), 2720 | 47.9 (47.8 to 47.9), 4063 | 47.8 (47.7 to 47.8), 4374 | 47.8 (47.7 to 47.8), 4374 44.7 (44.6 to 44.8), 3027 45.5 (45.4 to 45.6), 3381 | 45.5 (45.4 to 45.6), 3381 |
| Ever married | 89.7 (88.4 to 90.9), 5228 | 96.6 (95.9 to 97.1), 5794 | 86.0 (85.0 to 87.0), 7320 | 92.6 (91.6 to 93.6), 8565 | 91.7 (90.6 to 92.7), 5901 | 94.0 (93.3 to 94.6), 6373 |
| Ever tested for HIV | 86.4 (84.9 to 87.7), 5018 | 94.8 (94.0 to 95.4), 5756 | 95.7 (95.2 to 96.1), 8194 | 89.2 (88.2 to 90.1), 8206 | 92.3 (91.5 to 93.1), 5878 | 94.8 (94.1 to 95.4), 6375 |
| Location urban | 54.0 (48.8 to 59.1), 3215 | 19.0 (16.3 to 21.9), 2289 | 20.2 (16.5 to 24.5), 2159 | 39.4 (35.7 to 43.4), 3299 45.9 (42.4 to 49.4), 2867 | 45.9 (42.4 to 49.4), 2867 | 38.9 (37.0 to 40.9), 2317 |
| Education | | | | | | |
| No education | 22.1 (20.0 to 24.3), 1307 14.5 (13.2 to 15.9), 747 | 14.5 (13.2 to 15.9), 747 | 11.5 (10.7 to 12.4), 953 | 17.8 (16.3 to 19.5), 1816 8.5 (7.2 to 9.9), 545 | 8.5 (7.2 to 9.9), 545 | 1.8 (1.4 to 2.3), 135 |
| Primary | 38.7 (36.7 to 40.7), 2210 | 66.2 (64.4 to 68.0), 3672 | 68.1 (66.4 to 69.7), 5666 | 65.8 (64.2 to 67.4), 5931 | 51.8 (49.5 to 54.1), 3329 | 27.6 (26.1 to 29.2), 2044 |
| Secondary | 21.1 (19.6 to 22.7), 1230 | 21.1 (19.6 to 22.7), 1230 16.7 (15.3 to 18.3), 1351 | 15.8 (14.7 to 16.9), 1434 | 14.7 (13.5 to 15.9), 1297 | 30.3 (28.4 to 32.3), 1953 | 62.8 (61.1 to 64.4), 4146 |
| Higher | 18.1 (16.3 to 20.0), 1122 | 2.5 (2.1 to 3.0), 288 | 4.6 (3.9 to 5.5), 510 | 1.7 (1.3 to 2.1), 137 | 9.4 (8.0 to 11.1), 583 | 7.8 (6.5 to 9.2), 455 |
| Wealth quintiles | | | | | | |
| 1, lowest | 14.6 (12.5 to 17.0), 910 | 17.3 (15.7 to 19.1), 748 | 20.4 (18.3 to 22.7), 1600 | 18.3 (16.1 to 20.8), 1821 | 18.3 (16.1 to 20.8), 1821 16.3 (14.6 to 18.1), 1055 | 18.9 (17.3 to 20.6), 1530 |
| 2 | 16.1 (14.5 to 17.8), 972 | 18.5 (17.0 to 20.1), 863 | 19.2 (17.5 to 21.0), 1542 | 19.6 (18.0 to 21.4), 1807 | 19.6 (18.0 to 21.4), 1807 17.5 (16.1 to 19.0), 1140 | 18.4 (17.2 to 19.6), 1318 |
| 3 | 19.1 (17.6 to 20.6), 1144 19.7 (18.3 to 21.2), 957 | 19.7 (18.3 to 21.2), 957 | 19.5 (18.1 to 21.0), 1580 | 20.0 (18.3 to 21.8), 2063 | 20.0 (18.3 to 21.8), 2063 19.7 (17.9 to 21.7), 1258 | 17.5 (16.0 to 19.1), 1180 |
| 4 | 23.1 (21.3 to 25.0), 1356 | 20.7 (19.3 to 22.2), 1207 | 20.2 (18.7 to 21.9), 1662 | 20.5 (18.6 to 22.5), 1798 | 22.2 (20 to 24.6), 1424 | 21.4 (19.1 to 23.8), 1282 |
| 5, highest | 27.1 (24.5 to 29.9), 1500 | 23.7 (21.6 to 25.9), 2287 | 20.6 (18.1 to 23.3), 2182 | 21.6 (19.4 to 24.0), 1694 | 24.3 (21.7 to 27.1), 1506 | 23.9 (21.4 to 26.5), 1474 |
| Z | 5882 | 6062 | 8571 | 9186 | 6413 | 6784 |

Self-reported cervical precancer screening, proportions in percentages, Pearson's test with jack-knife 95% Cls, N is number of observations. Ethiopia dataset had an urban variable which was divided into population sizes <50000 and >50000. We classified a population size of <50000 as rural and >50000 as urban. § Estimate based on 25–49 observations and should be interpreted with caution.

[QR, Interquartile Range; PHIA, Population-Based HIV Impact Assessment.




Figure 1 Survey weighted proportions of 25–49-year-olds reporting being screened for cervical precancer by age groups, rural versus urban residence, education and wealth quintile by country (percentage, 95% CI) (PHIA 2015–2019).

DISCUSSION

This study examined cervical precancer screening inequalities related to age, residence, education and wealth in six sub-Saharan African countries—Ethiopia, Malawi, Rwanda, Tanzania, Zambia and Zimbabwe. We found that self-reported cervical precancer screening was low and inequitable. None of the countries reached onethird of 70% WHO cervical precancer screening target, 8 years away from the 2030 deadline. Self-reported cervical precancer screening rates ranged from 3.5% (95% CI 3.1% to 4.0%) in Rwanda to 17.1% (95% CI 15.8% to 18.5%) in Zambia and Zimbabwe (17.4% (95% CI 16.1% to 18.8%). However, women who were older, residing in urban areas, who were more educated and in the highest wealth quintile reported a higher uptake of cervical precancer screening than women who were younger, living in rural areas, who were uneducated and in the lowest wealth quintile. Age-related inequalities were the most common—observed in all six surveyed countries. Rural-urban, education and wealth-related inequalities were each observed in four countries, ranging from low to moderate in magnitude. We also observed high inequalities from combinations of inequalities in age group, residence (rural, urban), education level and wealth in a few countries. These results have policy implications for the rapid scale-up of equitable life-saving cervical precancer screening.

In this study, self-reported cervical precancer screening was lower than one-third of the WHO target of screening

70% of eligible women for cervical precancer by 2030, consistent with other studies conducted in the surveyed countries. Studies found that cervical precancer screening uptake ranged from 11% in Tanzania to 26.5% in Malawi, despite differences in methodologies used to estimate cervical precancer screening. Countries should urgently scale up cervical precancer screening to meet the WHO cervical precancer screening target, removing inequalities that prevent some women from accessing screening for cervical precancer, and integrate cervical precancer screening in maternal, HIV, sexual and reproductive health, and social protection programmes.

Evidence supports the finding that inequalities in these underserved cervical precancer screening countries favoured women who were older, resided in urban areas, were more educated and in the highest wealth quintile than women who were younger, who lived in rural areas, were uneducated and in the lowest wealth quintile. 9 17 18 Studies conducted in Ethiopia, Rwanda, Tanzania, Zambia and Zimbabwe, also support this finding. 10-15 34-36 A study of 18 resource-constrained countries, of which eight were from sub-Saharan Africa further found that wealth status increased socioeconomic inequalities in cervical precancer screening, whereas being married, unemployed and living in urban communities reduced it.9 The results of this study agree with existing evidence on socioeconomic inequalities in maternal health. A study in Malawi found that rural-urban residence, education and wealth status significantly impacted the uptake of three

BMJ Open: first published as 10.1136/bmjopen-2022-067948 on 20 June 2023. Downloaded from http://bmjopen.bmj.com/ on June 29, 2023 at University of Basel. Protected by copyright.

Survey weighted differences in self-reported cervical precancer screening among 25-49 years old by age groups, rural-urban location, education and wealth Table 2

| quintile by country — (ORs((95% CI)) (PHIA 2015-2019) | HIA 2015–2019) | | | | | |
|---|----------------------|---------------------|---------------------|----------------------|---------------------|---------------------|
| Inequality dimensions | Ethiopia | Malawi | Rwanda | Tanzania | Zambia | Zimbabwe |
| Age (years) 35-49 (ref 25-34) | 1.90 (1.48 to 2.43) | 1.77 (1.39 to 2.27) | 1.46 (1.11 to 1.93) | 2.32 (1.85 to 2.91) | 1.50 (1.28 to 1.75) | 2.31 (1.92 to 2.78) |
| Residence urban (ref: rural) | 1.65 (1.02 to 2.65) | 1.91 (1.29 to 2.82) | 1.67 (1.05 to 2.65) | 1.57 (1.03 to 2.41) | 1.27 (0.96 to 1.68) | 0.90 (0.65 to 1.24) |
| Education primary (ref. no education) 0.97 (0.60 to 1.54) | 0.97 (0.60 to 1.54) | 1.04 (0.74 to 1.48) | 1.84 (1.04 to 3.26) | 0.91 (0.61 to 1.36) | 1.45 (0.97 to 2.16) | 0.78 (0.44 to 1.38) |
| Secondary | 1.32 (0.77 to 2.29) | 1.69 (1.11 to 2.58) | 3.11 (1.69 to 5.71) | 1.19 (0.70 to 2.00) | 1.81 (1.19 to 2.75) | 1.10 (0.63 to 1.94) |
| Higher | 1.73 (1.02 to 2.93)* | 2.10 (1.28 to 3.44) | 2.08 (0.99 to 4.38) | 1.38 (0.71 to 2.67) | 2.52 (1.61 to 3.94) | 1.95 (1.05 to 3.60) |
| Wealth quintiles | | | | | | |
| Q2 (ref: lowest Q1) | 0.92 (0.46 to 1.85) | 1.42 (0.85 to 2.36) | 1.00 (0.60 to 1.66) | 1.39 (0.78 to 2.49) | 0.98 (0.61 to 1.58) | 1.38 (1.00 to 1.91) |
| 03 | 1.63 (0.75 to 3.51) | 1.57 (0.97 to 2.55) | 1.32 (0.81 to 2.15) | 1.72 (1.07 to 2.77) | 2.24 (1.51 to 3.34) | 2.04 (1.47 to 2.85) |
| 0.4 | 1.78 (0.80 to 3.97) | 2.16 (1.32 to 3.53) | 1.25 (0.77 to 2.04) | 1.93 (1.08 to 3.44) | 2.40 (1.54 to 3.74) | 3.24 (2.19 to 4.82) |
| Q5 highest quintile | 2.13 (0.96 to 4.75) | 3.53 (2.15 5.80) | 1.34 (0.74 to 2.43) | 2.44 (1.31 to 4.54)7 | 4.01 (2.51 to 6.40) | 4.95 (3.17 to 7.70) |
| Goodness-of-fit Prob>F | 0.4317 | 0.9611 | 0.9176 | 0.9082 | 0.9569 | 0.9791 |
| | F(9, 17) = 1.07 | F(9, 17) = 0.31 | F(9, 17) = 0.40 | F(9, 17) = 0.42 | F(9, 17) = 0.32 | F(9, 17) = 0.25 |
| Z | 5850 | 6053 | 8553 | 9167 | 6375 | 6777 |
| | | | | | | |

Pearson test with jack-knife 95% CIs for cell proportions, n=number of observations. Significance was set at p=0.05. Goodness-of-fit test (Prob>). Ethiopia data set only had an urban variable. We classified an urban population size <50 000 as rural and >50 000 as urban. The regressions also controlled for the dummy variables province for Rwanda, Zambia and Zimbabwe; region for Ethiopia; zone for Malawi; and mainlandzanziba for Tanzania. The results are not included. Q 1—lowest wealth quintile, Q 2, Q 3, Q 4, Q 5—highest wealth quintile. "Not significant after correcting for multiple hypothesis testing with the sharpened Qs. N, number of observations; PHIA, Population-Based HIV Impact Assessment.




Figure 2 Survey weighted differences in probabilities of self-reported cervical precancer screening by combinations of age group, rural-urban residence, no education, higher education and lowest to highest wealth quintiles by country. Marginal effects (percentages, 95% CI) (PHIA 2015-2019). PHIA, Population-Based HIV Impact Assessment. 1=lowest wealth quintile, 2, 3, 4, 5=highest wealth quintile. 25-34# = 25 - 34-year-olds; 35-49# = 35 - 49-year-olds. #Rural=rural. #Rich=rich. Noed=no education, Prim=primary, High=higher education. PHIA, Population-Based HIV Impact Assessment.

types of maternal health services in the study population. It found that compared with women residing in rural areas, who had lower education and were in the poorest wealth quintile, women living in urban areas, who had higher education and were in the higher wealth quintiles had significantly higher odds of receiving four antenatal care visits, skilled birth attendance and postnatal care.³⁷ A study from Zambia reported similar findings.³⁸ So did a study from 36 sub-Saharan African countries, concluding that prioritising quality education of women in sub-Saharan Africa would reduce disparities in antenatal service utilisation.³⁹ Countries should urgently scale-up cervical precancer screening, addressing inequalities that prevent some women from accessing services.

This study also determined the magnitude of the socioeconomic inequalities in reported cervical precancer screening to aid policy-making in the prioritisation of inequalities to eliminate in the scale-up of cervical precancer screening. We found low to moderate age, rural-urban, education and wealth-related inequalities in cervical precancer screening in the surveyed countries. Age-related inequalities were reported in all the surveyed countries and residence, education and wealthrelated inequalities in four of the six surveyed countries. Although the inequalities were low to moderate, our study found that their combined effects on cervical precancer screening probabilities were substantial, especially in countries with higher rates of self-reported cervical precancer screening. The inequalities in cervical precancer screening rates between rural residents aged 25-34, with no education in the lowest wealth quintile, and their urban resident peers, with highest education in the highest wealth quintile, ranged from low inequalities in Rwanda, to moderate inequalities in Ethiopia and Tanzania to high inequalities in Malawi, Zambia and Zimbabwe. Comparing primary educated rural residents aged 25-35 years old, in the lowest wealth quintile with the highest educated urban residents aged 35-49 years old, in the highest wealth quintile showed substantial differences. Inequalities did not disappear between the 25–34 years old most affluent, highest educated, urban residents, and 35-49 years old, most affluent, highest educated, urban residents. These results suggest that inequalities persist. Minor or moderate inequalities compound into high inequalities, further leaving women behind in cervical precancer screening. Starting with age-related inequalities, eliminating socioeconomic inequalities should be prioritised in the urgent scale-up of cervical precancer screening interventions.

Comparing the proportion of HIV-positive women in the sample and their reported cervical precancer screening showed cervical precancer screening gaps among HIVpositive women. In our study, the proportion of HIVpositive 25-49 years old women ranged from 4.7% (95% CI 4.1% to 5.4%) in Rwanda to 22.6% (95% CI 21.6% to 23.7%) in Zimbabwe. By contrast, self-reported cervical precancer screening among this population ranged from 0.4% (95% CI 0.3% to 0.5%) in Rwanda to 5.4% (95% CI 4.7% to 6.1%) in Zambia. Not all HIV-positive women were screened for cervical precancer for several reasons. One reason may be the perception that linking women testing HIV-positive to HIV treatment eliminates the risk of cervical precancer for such women. A study in Zimbabwe found that many women living with HIV on ART screened positive for cervical precancer, despite the country attaining HIV treatment targets. 40 Another reason women may have not been screened for cervical precancer is that they may have tested HIV-positive at a facility with a limited capacity to conduct cervical precancer screening. Alternatively, women might have been unable to access health facilities with the capacity to test for cervical precancer for various reasons, including transport costs. A large proportion of HIV-negative women who were tested for HIV in this study were not screened for cervical precancer. One reason is the perception that HIV-negative women may be at low risk of cervical precancer. 14 Integration between HIV testing and cervical precancer screening is required and is feasible in the scale up of cervical precancer screening. 41 Increased resources for HIV testing, training and orientation of healthcare staff to screen eligible women for cervical precancer, including HIV-negative women, is required to scale up screening services and reduce inequalities in the uptake of services.

Besides intensifying cervical precancer screening in HIV programmes, governments should fulfil their obligations to the right to sexual and reproductive health by increasing the accessibility of their health systems.⁸ They should reorient the building blocks of health systems—governance, financing, human resources, information, medical technologies and service deliverytowards addressing inequalities and reaching all eligible women.⁸ ⁴² They should establish, fund and scale-up population-level public-sector screening and treatment services and integrate them into HIV, STI, maternal and reproductive health services. 43 Governments could build cervical precancer screening around a target population, such as eligible schoolgirls and college students, which would assist in addressing socioeconomic inequalities. For example, Rwanda vaccinated more than 90% of schoolgirls against HPV from 2011 to 2012, through designated 'health days' adapted for other sexual reproductive and maternal health purposes. 44 45 This approach reduced time, money and other costs of accessing HPV vaccination for girls, and other maternal health services for women.44 In contrast to other countries surveyed in this study, none of the wealth levels were associated with cervical precancer screening in Rwanda. However, the cervical precancer screening rate in Rwanda in this study was low at 3.5% (3.1%-4.0%), illustrating that cervical precancer screening did not scale-up as did the HPV vaccination. 45 Additional activities may be added to

such programmes to increase access and reduce inequalities. These include multiple screening over the lifetime, reducing the perception of high economic costs associated with cervical precancer screening, and instituting same-day cervical precancer screening and treatment. 46 Other recommendations are the removal of economic barriers and focused outreach to women less likely to be screened and allowing them to self-collect samples. 1 15 46 Women's ability to benefit from these programmes may depend on their social health protection, such as whether they have childcare responsibilities that prevent them from accessing services.²¹ Women with multiple inequalities depend on social protection and may be vulnerable under systems with low social protection.²¹ Governments should expand their social protection coverage and enhance their health system accessibility to scale up cervical precancer screening, addressing the socioeconomic inequalities that prevent women from accessing services.21

This study has several limitations. Collinearity was present, especially between the wealth and residence variables which tend to correlate with each other, consistent with how the wealth variable is constructed. Recall bias was present as cervical precancer screening is self-reported. We did not control for the type of cervical precancer screening because we did not have information on the types of screening women received. Cervical precancer screening uptake may have worsened because of the COVID-19 pandemic. We did not determine if women had received two screenings by age 45 years as recommended by WHO, which could change our results. However, we used high-quality population-based data providing useful study findings to countries in sub-Saharan Africa.

Cervical precancer screening in the surveyed countries was inequitable and low—less than one-third of the WHO target to screen 70% of eligible women by 2030 for cervical precancerous lesions. Women who were younger, lived in rural areas, had no education and were from poor backgrounds were left behind in cervical precancer screening. Age-related inequalities were the most common type of inequalities observed. In combination, inequalities related to age, residence, education and wealth left further behind women who were younger, resided in rural areas, were uneducated, and poor. Focused and inclusive national cervical precancer interventions are required to scale-up equitable cervical precancer screening. Governments should include and monitor equity in their cervical precancer screening programmes. Research is needed to understand how to scale-up equitable cervical precancer screening in sub-Saharan Africa countries.

Author affiliations

¹ERA, UNAIDS, Geneve, Switzerland

²Faculty of Medicine, University of Geneva, Geneve, Switzerland

³World Health Organization, Harare, Zimbabwe

⁴Kamuzu University of Health Sciences, Blantyre, Malawi

⁵Clinic, Newlands Clinic, Harare, Zimbabwe

⁶Department of Economics, University of Lausanne, Lausanne, Switzerland

⁷Swiss Tropical and Public Health Institute, University of Bern, Basel, Switzerland

Twitter David Chipanta @ChipantaD

Acknowledgements We acknowledge the support from the Swiss National Science Foundation (SNSF) grant number 202660.

Contributors DC designed the study and DC is the gaurantor. DC and SA collated the data. DC, SA-A, SK, ALN-M, MP, JB, JE and OK performed the data analysis. DC conducted the data visualisation, drafted and revised the manuscript. SA-A, SK, ALN-M, MP, JB, JE and OK critically reviewed the drafts. All authors approved the final manuscript.

Funding This manuscript was supported by Swiss National Science Foundation (SNSF) grant number 202660.

Disclaimer Where authors are identified as personnel of the International Agency for Research on Cancer / World Health Organization or UNAIDS, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer / World Health Organization or UNAIDS.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants but the study did not need ethical clearance because the data are deidentified and publicly available at https://phia-data.icap.columbia.edu/files. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available in a public, open access repository. The data are deidentified and publicly available at https://phia-data.icap.columbia.edu/files.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iDs

David Chipanta http://orcid.org/0000-0002-7909-6855
Sharon Kapambwe http://orcid.org/0000-0001-9800-9385
Alinane Linda Nyondo-Mipando http://orcid.org/0000-0002-3572-3810
Margaret Pascoe http://orcid.org/0000-0003-3066-3780
Silas Amo-Agyei http://orcid.org/0000-0001-9718-6363
Julia Bohlius http://orcid.org/0000-0003-1955-1585
Janne Estill http://orcid.org/0000-0001-9544-1447
Olivia Keiser http://orcid.org/0000-0001-8191-2789

REFERENCES

- 1 World Health Organization. Global strategy to accelerate the elimination of Cervical cancer as a public health problem. Geneva, 2020.
- World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention. Geneva, 2021. Available: https://apps.who.int/iris/handle/ 10665/336583
- 3 Rohner E, Bütikofer L, Schmidlin K, et al. Cervical cancer risk in women living with HIV across four continents: A Multicohort study. Int J Cancer 2020;146:601–9.
- 4 Campos NG, Sharma M, Clark A, et al. The health and economic impact of Scaling Cervical cancer prevention in 50 Low-

- and lower-middle-income countries. *Int J Gynaecol Obstet* 2017:138 Suppl 1:47–56.
- 5 World health Organizaation (WHO). Health equity. [Online]. 2021. Available: https://www.who.int/health-topics/health-equity#tab= tab 1
- 6 Delavari S,M, Bayati M. Global socioeconomic inequality in the burden of Communicable and non-Communicable diseases and injuries: an analysis on global burden of disease study 2019. BMC Public Health 2021:1771.
- 7 Doorslaer Ev O, Wagstaff A, Lindelow M. Analyzing health equity using Household Survey Data. A guide to techniques and their Implementation. Washington DC: The International Bank for Reconstruction and Development / The World Bank, 2008.
- 8 Perehudoff K, Vermandere H, Williams A, et al. Universal Cervical cancer control through a right to health lens: refocusing national policy and programmes on Underserved women. BMC Int Health Hum Rights 2020;20.
- 9 Mahumud RA, Keramat SA, Ormsby GM, et al. Wealth-related inequalities of women's knowledge of Cervical cancer screening and service utilisation in 18 resource-constrained countries: evidence from a pooled decomposition analysis. Int J Equity Health 2020;19.
- 10 Ayenew AA, Zewdu BF, Nigussie AA. Uptake of Cervical cancer screening service and associated factors among age-eligible women in Ethiopia: systematic review and meta-analysis. *Infect Agents Cancer* 2020;15:67.
- 11 Kluge U, A, Borde T, Mchome B, et al. Tanzanian Women's knowledge about Cervical cancer and HPV and their prevalence of positive VIA Cervical screening results. Glob Health Action 2020.
- Weng Q, Jiang J, Haji FM, et al. Women's knowledge of and attitudes toward Cervical cancer and Cervical cancer screening in Zanzibar, Tanzania: a cross-sectional study. BMC Cancer 2020;20:63.
- 13 Barrow A, Onikan A, Nzoputam CI, et al. Prevalence and determinants of Cervical cancer awareness among women of reproductive age: evidence from Benin and Zimbabwe populationbased data. Appl Cancer Res 2020;40.
- 14 Moucheraud C, Kawale P, Kafwafwa S, et al. It is big because it's ruining the lives of many people in Malawi": Women'Sattitudes and beliefs about Cervical cancer. Prev Med Rep 2020;18:101093.
- 15 Pry JM, Manasyan A, Kapambwe S, et al. Cervical cancer screening outcomes in Zambia, 2010-19: a cohort study. Lancet Glob Health 2021;9:e832–40.
- Nyambe A, Kampen JK, Baboo SK, et al. Knowledge, attitudes and practices of Cervical cancer prevention among Zambian women and men. BMC Public Health 2019;19:508. 10.1186/s12889-019-6874-2 Available: https://doi.org/10.1186/s12889-019-6874-2
- 17 Kawale P,R, Corrina M. Cervical cancer prevention in Africa: A policy analysis. J Cancer Policy 2022.
- 18 Akokuwebe ME, Idemudia ES, Lekulo AM, et al. Determinants and levels of Cervical cancer screening uptake among women of reproductive age in South Africa: evidence from South Africa demographic and health survey data, 2016. BMC Public Health 2021:21:2013
- 19 Keetile M, Ndlovu K, Letamo G, et al. Factors associated with and socioeconomic inequalities in breast and Cervical cancer screening among women aged 15–64 years in Botswana. PLoS ONE 2021;16:e0255581.
- 20 Quizhpe E, Sebastian MS, Teran E, et al. Socioeconomic inequalities in women's access to health care: has Ecuadorian health reform been successful Int J Equity Health 2020;19:178.
- 21 Jolidon V,VD, Willems B, Cullati S, et al. n.d. Cervical cancer screening programs and their context-dependent effect on inequalities in screening uptake: a dynamic interplay between public health policy and welfare state redistribution. Int J Equity Health:211.
- 22 Jolidon V, De Prez V, Willems B, et al. Never and under Cervical cancer screening in Switzerland and Belgium: trends and inequalities. BMC Public Health 2020;20:1517.
- 23 Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of Cervical cancer associated with HIV. Lancet Glob Health 2021:9:e161–9.
- 24 Ministry of Health, Ethiopian Public Health Institute, Federal HIV/ AIDS Prevention and Control Office, Central Statistical Agency of Ethiopia, Ethiopian Public Health Association. Ethiopia Populationbased HIV Impact Assessment 2017-2018 (EPHIA2017-2018) (various datasets). Lilongwe: MOH, National AIDS Commission, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP at Columbia University [Distributor], 2021.
- 25 Ministry of Health (MOH). Malawi Population-Based HIV Impact Assessment 2015-2016(MPHIA 2015-2016) (various) [Datasets]. Lilongwe: MOH, National AIDS Commission, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP at ColumbiaUniversity [Distributor], 2021.



- 26 Government of Rwanda, Rwanda Biomedical Centre, National Institute of Statistics ofRwanda, University of Rwanda, World Health Organization, Rwanda United NationsChildren's Fund (UNICEFRwanda Population-based HIV Impact Assessment 2018-2019(RPHIA 2018-2019) (various datasets). Kigali: Government of Rwanda, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP at Columbia University[Distributor], 2021.
- 27 TACAIDS, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP atColumbia University [Distributor]. *Tanzania HIV Impact Survey 2016 - 2017 (THIS 2016-2017)*. Dar es Salaam, 2021.
- 28 Ministry of Health, Zambia National Public Health Institute, National HIV/AIDS/STI/TBCouncil Zambia, University of Zambia, Central Statistical Office Zambia, Tropical DiseaseResearch Centre, University Teaching Hospital, ZambiaZambia Population-based HIVImpact Assessment 2016 (ZAMPHIA 2016) (various datasets). Lusaka: MOH, National HIV/AIDS/STI/TB Council Zambia, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP at Columbia University [Distributor], 2021.
- 29 Ministry of Health and Child Care Zimbabwe, Zimbabwe National Statistics Agency, Biomedical Research and Training Institute, Lancet Clinical, Zimbabwe Statistical Centerfor HIV/AIDS Research and Prevention Zimbabwe Population-based HIV ImpactAssessment 2015 - 2016 (ZIMPHIA 2015-2016). Harare: MoHCC, PEPFAR, CDC, Westat, ICAP at Columbia University [Producers]. ICAP at Columbia University [Distributor], 2021.
- 30 World Health Organization. State of inequality: HIV, tuberculosis and malaria. Geneva: World Health Organization, 2021.
- 31 HIV Impact Assessment (PHIA). Data Use Manual. New York, 2019.
- 32 HIV Impact Assessments (PHIA) Project. Population-based HIV impact assessments (PHIA) guiding the global AIDS response. 2021. Available: https://phia-data.icap.columbia.edu/files
- 33 Davies L,G, Goodman D, Batalden P, et al. SQUIRE 2.0 (standards for quality improvement reporting excellence): revised publication Guideliness from a detailed consensus process. BMJ Qual Saf 2015.
- 34 Niyonsenga G, Gishoma D, Sego R, et al. Knowledge, utilization and barriers of Cervical cancer screening among women attending selected district hospitals in Kigali - Rwanda. Can Oncol Nurs J 2021;31:266–74.
- 35 Kabatsinda A,I, Ndabarora E. Uptake of Cervical cancer screening and associated factors among women attending outpatient services

- in Rwamagana hospital, Rwanda. Rwanda Journal of Medicine and Health Sciences 2021.
- 36 Kapambwe S, Sahasrabuddhe VV, Blevins M, et al. Implementation and operational research: age distribution and determinants of invasive Cervical cancer in a "screen-and-treat" program integrated with HIV/AIDS care in Zambia. J Acquir Immune Defic Syndr 2015;70:e20-6.
- 37 Yaya S, Bishwajit G, Shah V. Wealth, education and urban–rural and maternal Healthcare service usage in Malawi. BMJ Glob Health 2016;1:e000085.
- 38 Zhang C,Z, Wang S, Yang X. Socioeconomic determinants of maternal Healthcare utilisation in Zambia: 1997-2014. INQUIRY: The Journal of Health Care Organization, Provision, and Financing 2021;S8:1–14.
- 39 Obse AG, Ataguba JE. Explaining socioeconomic disparities and gaps in the use of Antenatal care services in 36 countries in sub-Saharan Africa. *Health Policy Plan* 2021;36:651–61.
- 40 Taghavi K, Mandiriri A, Shamu T, et al. Cervical cancer screening Cascade for women living with HIV: A cohort study from Zimbabwe. PLOS Glob Public Health 2022;2:e0000156. 10.1371/journal.pgph. 0000156 Available: https://doi.org/10.1371/journal.pgph.0000156)
- 41 Pfaff C, Singano V, Akello H, et al. Early experiences in integrating Cervical cancer screening and treatment into HIV services in Zomba central hospital. *Malawi Med J* 2018;30:211–4.
- 42 Gravitt PE, Silver MI, Hussey HM, et al. Achieving equity in Cervical cancer screening in Low- and middle-income countries (Lmics): strengthening health systems using a systems thinking approach. Preventive Medicine 2021;144:106322.
- 43 Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population-level scale-up of Cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the Cervical cancer prevention program in Zambia. PLoS ONE 2015;10:e0122169.
- 44 Ngabo F,A, Wagner CM, Gatera M, et al. Lessons from the field. Bulletin of the World Health Organisation 2013;91:697–703.
- 45 Muhimpundu M-A, Ngabo F, Sayinzoga F, et al. Initial results of Cervical cancer screening and treatment in Rwanda. JCO Glob Oncol 2021;7:GO.20.00147:632–8.:.
- 46 Campos NG, Tsu V, Jeronimo J, et al. Evidence-based policy choices for efficient and equitable Cervical cancer screening programs in low-resource settings. Cancer Med 2017;6:2008–14.